Projects

iBET has been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable impact internationally at many scientific and technological domains.
Filters
biopharma ongoing international

Austrian Centre of Industrial Biotechnology, Karlsruche Institute of Technology, Leiden University Medical Center, Hamburg University, ICOSAGEN, FAU

MSCA Doctoral Network CAARE: Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy
EC-HORIZON-MSCA-2023-DN-01
October 01, 2024 — September 30, 2028
biopharma ongoing national

ILevAA – Integrating Continuous Production and Purification for Leveraging Recombinant Adeno-Associated Viruses (rAAV) Manufacturing
Fundação para a Ciência e Tecnologia (FCT)
January 01, 2025 — December 31, 2025
sustainability-food-health ongoing national

PePOP – Recovery of bioactive peptides from olive pomace
Fundação para a Ciência e Tecnologia (FCT)
January 01, 2025 — June 30, 2026
biopharma ongoing national

eiMACpro – Engineering hiPSC-derived macrophages (eiMAC) with tunable pro-inflammatory phenotype
Fundação para a Ciência e Tecnologia (FCT)
February 03, 2025 — August 02, 2026
biopharma ongoing international

14 Partners Across 7 European Countries

MSCA Doctoral Network ORGESTRA: Advancing Organoid Technologies Through Joint Doctoral Training
EC HORIZON–MSCA-2023-DN-JD
March 01, 2024 — December 31, 2027
biopharma ongoing international

OneChain Immunotherapeutics, Josep Carreras Leukemia Research Institute, Severo Ochoa Center for Molecular Biology

CARxALL – A new therapeutic opportunity for t-cell acute lymphoblastic leukemia patients
European Innovation Council (EIC) - Transition Program
April 01, 2023 — March 31, 2026
biopharma ongoing international

Non-profit European Research Infrastructure Consortium

EATRIS – European Infrastructure for Translational Medicine
biopharma ongoing international

34 International Partners

ARDAT – Accelerating Research & Development for Advanced Therapies
Innovative Medicines Initiative - European Commission
November 01, 2020 — October 31, 2025
biopharma ongoing international

Haplo-iPS – Generation of Human Induced Pluripotent STEM Cells from Haplo-selected Cord Blood Samples
COST ACTION CA21151
October 11, 2022 — October 10, 2026
biopharma ongoing national

EXCELERATE – Advancing the manufacturing of EXtracellular vesicles derived from human pluripotent stem CELls for cardiac rEgeneRATive medicine
FCT - Fundação para a Ciência e Tecnologia
January 01, 2023 — December 31, 2025
sustainability-food-health ongoing national

18 national partners

TEC4GREEN – Preparing the agro-industrial sector for future technological and environmental challenges
Recovery and Resilience Program
July 01, 2022 — December 31, 2025
sustainability-food-health ongoing national

Instituto Politécnico de Bragança, MORE- Laboratório Colaborativo Montanhas de Investigação, UTAD - Centro de Investigação e de Tecnologias Agro-Ambientais e Biológicas

Mush4Chol – Development of an efficient hypocholesterolemic formulation from mushroom bioresidues through a sustainable integrated strategy
FCT - Fundação para a Ciência e Tecnologia
March 01, 2023 — February 28, 2026
sustainability-food-health ongoing national

ITQB NOVA, FCT NOVA

LEDeffect – Understanding the mechanisms of inactivation of ultraviolet light emitting diodes to develop effective water disinfection systems
FCT - Fundação para a Ciência e a Tecnologia
March 01, 2022 — October 31, 2025
sustainability-food-health ongoing national

IPO Lisboa, NOVA FCT

VOOmics – OMICs approaches to reveal the anticancer properties of Virgin Olive Oil
FCT - Fundação para a Ciência e Tecnologia
January 01, 2022 — December 31, 2024
biosustainability ongoing national

VIIAFOOD
Recovery and Resilience Plan
July 01, 2022 — December 31, 2025
sustainability-food-health ongoing international

A4F, iBET, LNEG, IMIC CAS, PhyCom, For Farmers, International Flavors & Fragrances, Upfield

MULTI-STR3AM – Towards Industrial-scale Microalgae Cultivation in Europe
Horizon 2020
May 01, 2020 — April 30, 2025
biopharma concluded international

Navarra Univ., Zaragoza Univ., EBERS, SaludMadrid, PNO, Leartiker S. Coop, IBEC, Eindhoven Univ., UMC Utrecht, AE Medicalis, KU Leuven, Univ. Hospital Würzburg, Boston Scientific

BRAV3 – A Cardiac Regenerative Medicine European Initiative
European Comission
October 01, 2020 — June 30, 2025
biopharma concluded national

iBET Biofarma Building – Technological Infrastructure
Portugal2020, Lisboa2020, European Union
December 20, 2022 — August 31, 2023
sustainability-food-health concluded international

GreenPlantFood – Green technology for plant-based food
Norwegian Research Council
April 01, 2021 — March 01, 2025
biopharma concluded international

Nine Partners from Spain, Portugal and France

CARDIOPATCH: Development of Advanced Therapies of Myocardial Infarction Treatment based on Regenerative Medicine and 3D Printing
Interreg SUDOE Programme - European Regional Dev. Fund
September 01, 2020 — September 01, 2023
biopharma concluded national

PRINTƎD – AAV PRocess INTensification with 3D printed materials
Fundação para a Ciência e Tecnologia
January 01, 2022 — June 30, 2023
biopharma concluded national

CARTool – A process engineering approach for manufacturing CAR T cells in biOreactOrs with improved cLinical revelance
FCT - Fundação para a Ciência e Tecnologia
March 01, 2023 — December 31, 2024
biopharma concluded international

University of Bristol, Liverpool School of Tropical Medicine, Liége Université, Aix Marseille Université

ADDovenom – Novel Snakebite Therapy Platform of Unparalleled Efficacy, Safety and Affordability
European Comission
October 01, 2020 — September 30, 2024
sustainability-food-health concluded national

SafeFood – Evaluate the effectiveness and effects of ultraviolet light‐emitting diodes for food production, preservation, and microbiological safety
FCT - Fundação para a Ciência e a Tecnologia
March 12, 2023 — September 11, 2024

Concluded Projects (Previous to 2020)

  • CARDIOCONTRACT: Automated Cardiomyocyte Contractility Assay Instrument.
    2018-2020, EUROSTARS-2 – 12529/19/Q
  • DiViNe – Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies: novel affinity ligands and biometric membranes.
    2015-2019, H2020-LEIT-BIO-1-635770. Funded by the EU
  • INNOVATE – Investigating the Novel Valuable bio-therapeutics and expression systems.
    2014-2017, ERA-IB-2/0007/2013, Funded by the EU
  • EDUFLUVAC – Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure.
    2013-2017, FP7-HEALTH-2013-INNOVATION. Funded by the EU.
  • EPIGENESIS – One Health approach to integrate Guadeloupe research on vector-borne and emerging diseases in the ERA.
    2013-2016, FP7-REGPOT-2012-2013-1, funded by the EU.
  • BRAINVECTORS— From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV.
    2012-2016, FP7-PEOPLE-2011-IAPP. Funded by the EU.
  • SpeCCC – Specialised Cell Carrier Components.
    2012-2015, FP7‐SME‐2012‐315717. Funded by the EU
  • NanoGene – Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells.
    2011-2014, ENMED/0001/2010, funded by EuroNanoMed ERA-Net.
  • PREDECT – New Models for Preclinical Evaluation of Drug Efficacy in common solid tumours.
    2011-2016, GRANT AGREEMENT No. 115188, funded by IMI (Innovative Medicines Initiative) Joint Undertaking, funded by EU.
  • ComplexINC – New Technologies and Production Tools for Complex Protein Biologics.
    2011-2015, FP7 / SME-targeted research for developing tools and technologies for high-throughput research, funded by EU.
  • CAREMI – Cardio Repair European Multidisciplinary Initiative.
    2010-2015, HEALTH-F5-2010-242038, funded by EU
  • HYPERLAB – high yield and performance stem cell lab.
    2009-2012, funded by EU (223011)
  • BrainCAV: Gene Transfer for Brain Therapy.
    2008-2012, funded by EU (FP7-222992)
  • CLINIGENE-NoE: European Network for the Advancement of Clinical Gene Transfer and Therapy.
    2006-2011, LSHB-CT-2006-018933, funded by the EU
  • VITROCELLOMICS – Reducing Animal Experimentation in Preclinical Predictive Drug Testing by Human Hepatic in vitro Models Derived from Embryonic Stem Cells.
    2006-2009, funded by EU (LSHB-CT-2006-018940)
  • BACULOGENES – Baculovirus Vectors for Gene Therapy.
    2006-2009, FP6 – 2007, funded by the EU
  • MARKVAC – Development of marker vaccines, companion diagnostic tests and improvement of epidemiological knowledge to facilitate control of rinderpest and peste des petits ruminants viruses.
    2005-2007, RP/PPR MARKVAC, funded by the EU
  • EPIGENEVAC – Epidemiology and new generation vaccines for Ehrlichia and Anaplasma infections of ruminants.
    2005-2009, FP6-003713-INCO-DEV-1, funded by the EU
  • CELLPROM – Cell Programming by Nanoscaled Devices.
    2004-2009, NMP4-CT-2004-500039, funded by the EU
  • INSERTAGENE – Integrated Strategies for efficient therapeutic retrovirus based on modular cell lines.
    2003-2005, QLK3-CT-2002-01949, funded by the EU
  • ROTASAFE – Novel strategies for a safe rotavirus vaccine.
    2003-2005, QLRT-2001-01249, funded by the EU
  • COWDRIA – Mass production of Cowdria ruminantium to produce a cost effective veterinary vaccine against heartwater.
    2001-2004, 8-ACP-TPS-040, funded by the EU
  • ORALVAC – Development of Oral Vaccines, Role of Wildlife in The Maintenance of these Diseases.
    2001-2004, ICA4-CT-2000-30027, funded by the EU
  • ERAdicatPH: Understanding primary hyperoxaluria type 1 towards the development of innovative therapeutic strategies.
    2016-2019, E-Rare3/0002/2015, funded by FCT, Portugal
  • Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands.
    2016-2019, PTDC/BBB-BMD/4497/2014, funded by FCT, Portugal
  • NETDIAMOND: New targets in diastolic heart failure: from comorbidities to personalized medicine.
    2016-2019, POCI-01-0145-FEDER-016385
  • CardioRegen: Integrative studies from the embryo to Scalable Multipronged Generation of hESC-derived Myocardial progenitors for heart repair.
    2015-2019, HMSP-ICT/0039/2013, HMS program, funded by FCT, Portugal
  • Engineering biosensors for human cell type and state diagnosis using synthetic digital computation.
    2018-2019, MIT-EXPL/BIO/0097/2017
  • Establishment of a flexible insect cell platform for fast production of pseudo-typed VLPs for drug and vaccine development.
    2014-2015, EXPL/BBB-BIO/1541/2013, funded by FCT, Portugal
  • Molecular approaches to develop an insect cell production system for Hepatitis C vaccine candidate.
    2014-2015, EXPL/BBB-BIO/1129/2013, funded by FCT, Portugal
  • Development of a scalable strategy for stem cells purification.
    2013-2014, EXPL/BBB-EBI/1003/2012, funded by FCT, Portugal.
  • Systems biotechnology for improved production of biopharmaceuticals in animal cells.
    2013-2015, PTDC/BBB-BSS/0518/2012, funded by FCT, Portugal.
  • Combining siRNA and AAV therapy approaches to target human basal-like breast cancer: from vector development to anti-tumor efficacy evaluation.
    2013-2015, PTDC/BBB-BIO/1240/2012, funded by FCT, Portugal.
  • Integrative approaches to depict human cardiac stem cell receptome and its role in the cardiac regenerative process.
    2013-2015, PTDC/BBB-BIO/1414/2012, funded by FCT, Portugal.
  • A novel generation of packaging cell lines for the manufacture of lentivirus based biopharmaceuticals.
    2012-2015, PTDC/EBB-BIO/118615/2010, funded by FCT, Portugal.
  • Development of improved suspension MDCK cell lines for the production of viral based bioproducts: manufacturing Influenza and Adenovirus.
    2012-2015, PTDC/EBB-EBI/118621/2010, funded by FCT, Portugal.
  • Human central nervous system in vitro models for preclinical research: new tools for studying viral vector-mediated gene.
    2012-2015, PTDC/EBB-BIO/119243/2010, funded by FCT, Portugal.
  • Probing adenovirus-host cell interactions: a systems biotechnology approach to improve production of gene delivery vectors.
    2012-2015, PTDC/EBB-BIO/119501/2010, funded by FCT, Portugal.
  • Development of function blocking antibodies using Phage Display Technology: Inhibiton of the Notch1 signaling pathway by function blocking anti-jagged 1 antibody.
    2012-2016, PTDC/SAU-ONC/121670/2010, funded by FCT, Portugal
  • MSVida: The architecture of life – Probing the quaternary structure of virus capsids by native mass spectrometry.
    2012-2016, RECI/BBB-BEP/0104/2012, funded by FCT, Portugal
  • 3D in vitro models for reducing animal experimentation in pharmaceutical development: integrative approaches for prediction of hepatic drug metabolism and neurotoxicity.
    2011-2014, PTDC/EBB-BIO/112786/2009, funded by FCT, Portugal.
  • Preconditioning triggered by Carbon monoxide: new strategies to prevent brain damage due to hypoxia-ischemia and reperfusion.
    2010-2012, PTDC/SAU-NEU/098747/2008, funded by FCT, Portugal.
  • 2D fluorometry: a powerful tool to improve mammalian cell process development.
    2010-2012, PTDC/EBB-EBI/102750/2008, funded by FCT, Portugal.
  • Novel Cell Factories for the production of secreted complex bioproducts: a syntetic biology approach for improved product Stoichiometries.
    2010-2012, PTDC/EBB-EBI/102266/2008, funded by FCT, Portugal.
  • BACULOME-Engineering cellular energetics for improvement of bioprocesses: metabolic modeling for enhanced vaccines production.
    2010-2012, PTDC/EBB-EBI/103359/2008, funded by FCT, Portugal.
  • Retroviral like particles: improving potential as candidate vaccines for Hepatitis C.
    2010-2012, PTDC/EBB-BIO/102649/2008, funded by FCT, Portugal.
  • Using functional genomics to improve mammalian cells for virus based biopharmaceuticals manufacture.
    2010-2012, PTDC/EBB-BIO/100491/2008, funded by FCT, Portugal.
  • Integrated strategies for expansion, neuronal differentiation and cryopreservation of human embryonic stem cells.
    2009-2012, funded by FCT (PTDC/BIO/72755/2006)
  • Fundamentals of downstream processing of enveloped viruses: towards an integration of purification processes.
    2007-2010, funded by FCT (PTDC/EQU-EQU/71645/2006)
  • Manufacturing canine adenovirus vectors for gene therapy: development of MDCK CAV-2E1- transcomplementing cell lines.
    2007-2010, funded by FCT (PTDC/BIO/69452/2006)
  • Development of flexible cell lines for the Production of Retrovirus and Lentivirus for Gene Therapy.
    2007-2010, funded by FCT (PTDC/BIO/69451/2006)
  • Novel stroke model for neuroprotective research: bioreaction of primary brain cell aggregates.
    2007-2010, funded by FCT (PTDC/BIO/69407/2006)
  • Carbon monoxide as a neuroprotective agent against hypoxia-ischemia and reperfusion.
    2007-2010, funded by FCT, Portugal (PTDC/SAU-NEU/64327/2006)
  • Advanced Control of BHK Cultivation Processes Based on Intracellular Metabolic Fluxes.
    2005-2007, funded by FCT, Portugal (POCI/BIO/57927/2004)
  • THERAVECT – Production, Purification and Storage of Retroviral Vectors Produced by Modular Master Producer Cells.
    2005-2007, funded by FCT, Portugal (010.6/A003/2005)
  • CELL CRYOTHERA – Cell Cryopreservation for Therapy and Regenerative Medicine.
    2005-2007, funded by FCT, Portugal (010.6/A006/2005)
  • Genetics, Stoicheometry and Kinetics of Multiple Protein Assembly: the case for a Rotavirus Like Particle.
    2005-2007, funded by FCT (POCTI/BIO/55975/2004)
  • Integrated strategy for the production, purification and storage of adenovirus.
    2004-2006, funded by FCT, Portugal (POCTI/BIO/46515/2002)
  • Metabolic Trafficking between neurons and astrocytes under stress conditions implicated in neurological disorders.
    2003-2006, funded by FCT, Portugal (POCTI/BIO/39214/2001)
  • Stabilization of retroviruses for gene therapy clinical applications.
    2001-2003, funded by FCT, Portugal (POCTI/BIO/35695/2000)
  • Cell cycle control for better biotechnological methods in therapeutic protein production.
    2001-2003, funded by FCT, Portugal (POCTI/BIO/35687/2000)